Metraipolis › archive › dc_03b8f1bbdff2

No evidence of direct activation of human neutrophil responses by multivalent prefusion trimeric SARS-CoV-2 Spike protein ex vivo — Europe PMC PMID:41160626

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41160626
DOI
10.1371/journal.pone.0332261
License (as archived)
CC0-1.0
Archived
2026-10-06T08:51:05.678Z
SHA-256 of the archived text
27a94f5567c617f7cb2aeaf9c897c647fe5d50029a6f74311878b9eb3280b952
Stable URL of this page
https://metraipolis.com/documento/dc_03b8f1bbdff2

How to cite

No evidence of direct activation of human neutrophil responses by multivalent prefusion trimeric SARS-CoV-2 Spike protein ex vivo — Europe PMC PMID:41160626 — Europe PMC (en), https://europepmc.org/article/MED/41160626 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_03b8f1bbdff2 (Metraipolis archive dc_03b8f1bbdff2, sha256 27a94f5567c617f7cb2aeaf9c897c647fe5d50029a6f74311878b9eb3280b952)
BibTeX
@misc{dc03b8f1bbdff2,
  title = {No evidence of direct activation of human neutrophil responses by multivalent prefusion trimeric SARS-CoV-2 Spike protein ex vivo — Europe PMC PMID:41160626},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41160626},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_03b8f1bbdff2; sha256 27a94f5567c617f7cb2aeaf9c897c647fe5d50029a6f74311878b9eb3280b952},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/41160626. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The SARS-CoV-2 Spike (S) protein is essential for viral entry and serves as the primary immunogen in most COVID-19 vaccines. While its role in adaptive immunity is well defined, its potential to contribute directly to innate immune activation remains incompletely understood. Neutrophils, in particular, are prominent effectors in COVID-19 severity, yet how they respond directly to the S protein presented in a multivalent format is unclear. Here, we investigated whether the S protein can directly activate human neutrophils ex vivo using two biologically relevant models: nanoparticles displaying multivalent stabilized prefusion trimeric S glycoprotein, and purified β-propiolactone-inactivated SARS-CoV-2 virions. Neutrophils were exposed to nanoparticles or inactivated virus, either alone or pre-coated with monoclonal or polyclonal anti-S antibodies. Nanoparticles displaying Respiratory Syncytial Virus (RSV) Fusion (F) protein and purified β-propiolactone-inactivated RSV served as comparators. Across all models and conditions tested, the S protein did not induce significant neutrophil responses. No consistent effects were observed on cell viability, surface marker expression, reactive oxygen species production, neutrophil extracellular trap formation, cytokine release, or inflammatory gene expression-even in the presence of anti-S antibodies mimicking immune complexes. Results with F-nanoparticles and inactivated RSV were similarly modest. These findings indicate that the trimeric prefusion S protein, whether displayed multivalently on nanoparticles or in the context of inactivated viral particles, is insufficient to trigger robust neutrophil activation. This work provides insight into the innate immune profile of the S protein and suggests that its use in vaccine platforms is unlikely to directly provoke neutrophil-mediated inflammatory responses.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-10-29).
Identificativi: PMID 41160626 · PMCID PMC12571262 · DOI 10.1371/journal.pone.0332261.
Descrittori MeSH principali: Neutrophils; Neutrophil Activation; Spike Glycoprotein, Coronavirus; COVID-19; SARS-CoV-2.
Pagina: https://europepmc.org/article/MED/41160626 — https://doi.org/10.1371/journal.pone.0332261. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T08:20:26.709Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.